SCHEMBL267064

SCHEMBL267064

Cc1ccc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2cccc(C(S)c3nc[nH]n3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.43
NPC1 O15118 6/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 4/20 0.41
PKM P14618 3/20 0.41
POLB P06746 4/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
GUSB P08236 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268412 0.93 RAB9A (0.47) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL266893 0.93 KMT2A (0.38) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL268527 0.92 MAPT (0.46) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL268532 0.91 NPC1 (0.44) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL266841 0.89 SLC34A2 (0.45) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL266176 0.86 SLC34A2 (0.37) RAB9ANPC1KMT2AMAPTPKM
SCHEMBL266694 0.85 NPC1 (0.48) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL269092 0.84 SLC34A2 (0.45) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL266118 0.83 SLC34A2 (0.47) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL270113 0.82 NPC1 (0.42) RAB9ANPC1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 RAB9A 883/4885NPC1 102/4885KMT2A 4564/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885NPC1 115/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.